Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
SUM1315MO2 Cisplatin
0.0010833
Chemo
Chemotherapy
 1.0113 -0.01160
HCC38 Bleomycin
0.0033333
Radiation
Misc
 1.0376 -0.01160
HCC1954 Abemaciclib
0.01
CDK4/6
Cell cycle
 0.8453 -0.01158
SK-BR-3 Vorinostat
0.0031623
HDAC
Misc
 1.0589 -0.01158
MDA-MB-134-VI Alpelisib
0.01
PI3Ka
PI3K/mTOR
 1.1674 -0.01158
HCC38 TGX221
0.31623
PI3Kb
PI3K/mTOR
 1.0777 -0.01157
CAL-85-1 Cediranib
0.031623
VEGFR/cKIT
RTK
 1.0238 -0.01155
MDA-MB-134-VI Vorinostat
0.01
HDAC
Misc
 1.2304 -0.01153
HCC1428 Dinaciclib
0.0031623
pan CDK
Cell cycle
 0.9874 -0.01140
HCC70 Abemaciclib
0.0031623
CDK4/6
Cell cycle
 1.3213 -0.01140
HCC70 Olaparib
0.01
PARP
Misc
 1.1636 -0.01138
CAL-51 Cisplatin
1.0
Chemo
Chemotherapy
 0.6953 -0.01136
CAL-51 Topotecan
0.0033333
Topo I
Chemotherapy
 0.9585 -0.01131
SUM159PT Bleomycin
0.0033333
Radiation
Misc
 0.9750 -0.01123
CAL-120 INK-128
0.0031623
mTORC1/2
PI3K/mTOR
 0.8476 -0.01120
PDXHCI002 Pictilisib
0.1
pan PI3K
PI3K/mTOR
 0.8837 -0.01119
SK-BR-3 Cabozantinib
3.1623
VEGFR2/MET
RTK
 1.0876 -0.01113
MDA-MB-134-VI Luminespib
0.001
HSP90
Misc
 1.4508 -0.01106
CAL-51 Palbociclib
0.01
CDK4/6
Cell cycle
 0.9110 -0.01105
HCC38 Etoposide
0.0010833
Topo II
Chemotherapy
 0.9819 -0.01103
PDX1328 Trametinib
0.0001
MEK
MAPK/nRTK
 1.1378 -0.01101
MDA-MB-468 Luminespib
0.001
HSP90
Misc
 1.0430 -0.01098
PDXHCI002 Ceritinib
0.031623
ALK
RTK
 0.9841 -0.01097
PDX1328 Etoposide
0.1
Topo II
Chemotherapy
 1.0051 -0.01095
PDX1258 Abemaciclib
0.0031623
CDK4/6
Cell cycle
 1.1002 -0.01094